Kalaris Therapeutics, Inc.
KLRS
$4.90
-$0.32-6.13%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Net Income | 54.61% | 68.77% | -100.88% | -199.27% | -534.57% |
| Total Depreciation and Amortization | -- | -- | -- | -- | -- |
| Total Amortization of Deferred Charges | -100.00% | -- | -100.00% | -76.54% | 597,966.67% |
| Total Other Non-Cash Items | 100.28% | -98.26% | 15.88% | 31.95% | -15,982.31% |
| Change in Net Operating Assets | 370.53% | -100.76% | -934.88% | 213.01% | -32.58% |
| Cash from Operations | 10.11% | -161.91% | -215.76% | -64.59% | -89.82% |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -- | -- | -- | -- | -- |
| Total Debt Issued | -100.00% | -- | -100.00% | 50.21% | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 2,099,900.00% | -- | -- | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -100.00% |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 339.37% | -- | 100.00% | 1,995,440.00% | -2,149.57% |
| Cash from Financing | 530.06% | -100.00% | -100.00% | 1,530.45% | 10.47% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 20,416.06% | -964.24% | -1,339.03% | 4,750.63% | -110.06% |